Average cost of multi drug-resistant tuberculosis treatment in Ghana
Ghana: Average cost of multi drug-resistant tuberculosis treatment was 500 constant 2022 US$ in 2024. ◆ Volatile
Average cost of multi drug-resistant tuberculosis treatment in Ghana, 2017–2024
Source: WHO (2025) – with minor processing by Our World in Data. Measured in constant 2022 US$.
Analysis
Ghana recorded 500 constant 2022 US$ for average cost of multi drug-resistant tuberculosis treatment in 2024. That is the lowest value across all 8 years on record.
Compared with earlier readings it is down 13.6% on the previous year and down 43.1% over ten years.
That places Ghana 78th out of 92 countries with data for 2024, putting it in the bottom quarter.
Average cost of multi drug-resistant tuberculosis treatment in Ghana, year by year
| Year | constant 2022 US$ | Change |
|---|---|---|
| 2017 | 879 constant 2022 US$ | — |
| 2018 | 2,200 constant 2022 US$ | +150.3% |
| 2019 | 2,500 constant 2022 US$ | +13.6% |
| 2020 | 1,200 constant 2022 US$ | -52.0% |
| 2021 | 1,200 constant 2022 US$ | +0.0% |
| 2022 | 2,100 constant 2022 US$ | +75.0% |
| 2023 | 579 constant 2022 US$ | -72.4% |
| 2024 | 500 constant 2022 US$ | -13.6% |
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 2010s | 1,860 constant 2022 US$ | 879 constant 2022 US$ | 2,500 constant 2022 US$ | 3 |
| 2020s | 1,116 constant 2022 US$ | 500 constant 2022 US$ | 2,100 constant 2022 US$ | 5 |
Countries ranked near Ghana
- 75 Peru 570 constant 2022 US$ compare
- 76 Angola 537 constant 2022 US$ compare
- 77 Madagascar 532 constant 2022 US$ compare
- 78 Cape Verde 500 constant 2022 US$ compare
- 80 Myanmar 468 constant 2022 US$ compare
- 81 Bangladesh 466 constant 2022 US$ compare
More health data for Ghana
- Un projection of annual infant deaths, annual growth rate -1.37 % change on previous year (2100)
- Heat deaths vs projected death rates, annual growth rate 0.6224 % change on previous year (2090)
- Estimated changes in temperature-related death rates compared to projected death rates 986.1 deaths per 1,000 people (2090)
- Number of infants who die before age 1 8,361 deaths (2100)
- Population ages 75-79, female, annual growth rate 3.61 % change on previous year (2025)
- Population ages 75-79, female, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 75-79, female, per capita 0.0036 units per person (2025)
- Population ages 75-79, male, annual growth rate 3.86 % change on previous year (2025)
- Population ages 75-79, male, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 75-79, male, per capita 0.0027 units per person (2025)
Frequently asked questions
- What is average cost of multi drug-resistant tuberculosis treatment in Ghana?
- Average cost of multi drug-resistant tuberculosis treatment in Ghana was 500 constant 2022 US$ in 2024, according to WHO (2025) – with minor processing by Our World in Data.
- What is the highest average cost of multi drug-resistant tuberculosis treatment recorded in Ghana?
- The highest recorded value was 2,500 constant 2022 US$ in 2019.
- What is the lowest average cost of multi drug-resistant tuberculosis treatment recorded in Ghana?
- The lowest recorded value was 500 constant 2022 US$ in 2024.
- How does Ghana rank for average cost of multi drug-resistant tuberculosis treatment?
- Ghana ranks 78th out of 92 countries with data for 2024.
- Is average cost of multi drug-resistant tuberculosis treatment rising or falling in Ghana?
- Over the last ten years it is down 43.1%. The long-run trend across the full record is volatile.
- Where does this Ghana data come from?
- The figures come from WHO (2025) – with minor processing by Our World in Data, published as part of Average cost of multi drug-resistant tuberculosis treatment. Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 8 observations, free to reuse under CC BY 4.0 (Our World in Data).
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.